Guoyan Zhu Selected Research

C 684

10/2021

Generation of a CRISPR/Cas9-corrected-hiPSC (NCCDFWi001-A-1) from a Marfan syndrome patient hiPSC with a heterozygous c.2613A>C variant in the fibrillin 1 (FBN1) gene.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guoyan Zhu Research Topics

Disease

3	Thoracic Aortic Aneurysm 02/2022 - 12/2021
2	Inflammation (Inflammations) 02/2022 - 01/2022
1	Aortic Rupture 02/2022
1	Thoracic Aorta Dissection 01/2022
1	Aortic Aneurysm (Aneurysm, Aortic) 01/2022
1	Marfan Syndrome (Marfan's Syndrome) 10/2021
1	Aneurysm (Aneurysms) 10/2018

Drug/Important Bio-Agent (IBA)

3	1,3,4,6- tetra- O- acetyl- 2- azido- 2- deoxyglucopyranose (TAAD)IBA 02/2022 - 12/2021
1	RNA (Ribonucleic Acid)IBA 02/2022
1	N- (4- ((6,7- dimethoxy- 4- quinolyl)oxy)- 2- methoxyphenyl)- N'- (1- (1,3- thiazole- 2- yl)ethyl)ureaIBA 02/2022
1	Matrix Metalloproteinases (MMPs)IBA 01/2022
1	thermozymocidin (myriocin)IBA 01/2022
1	AminopropionitrileIBA 01/2022
1	CeramidesIBA 01/2022
1	LipopolysaccharidesIBA 01/2022
1	MetalloproteinsIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Fibrillin-1IBA 10/2021
1	C 684IBA 10/2021
1	Transforming Growth Factor-beta Type II ReceptorIBA 10/2018

Therapy/Procedure

2	Therapeutics 02/2022 - 01/2022
1	Drug Therapy (Chemotherapy) 01/2022
1	Ligation 10/2018